Startseite>>Signaling Pathways>> Antibody-drug Conjugate/ADC Related>> Drug-Linker Conjugates for ADC>>MC-Val-Cit-PAB-dimethylDNA31

MC-Val-Cit-PAB-dimethylDNA31

Katalog-Nr.GC36570

MC-Val-Cit-PAB-DimethylDNA31 ist ein Wirkstoff-Linker-Konjugat fÜr ADC mit starker AntitumoraktivitÄt unter Verwendung von DimethylDNA31, verknÜpft Über den ADC-Linker MC-Val-Cit-PAB. DimethylDNA31 hat eine wirksame bakterizide AktivitÄt gegen Persister und S. aureus in der stationÄren Phase.

Products are for research use only. Not for human use. We do not sell to patients.

MC-Val-Cit-PAB-dimethylDNA31 Chemische Struktur

Cas No.: 1639352-06-9

Größe Preis Lagerbestand Menge
1mg Please Inquire Please Inquire
5mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

MC-Val-Cit-PAB-dimethylDNA31 has a bioreversible linkage based on a quaternary ammonium for targeted delivery and it can improve pharmacokinetics and the therapeutic index. MC-Val-Cit-PAB-dimethylDNA31 is used for the antibody-drug conjugates (ADC) that are effective and stable in vitro and in vivo to treat various diseases or disorders[1].

[1]. Staben LR, et al. Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates. Nat Chem. 2016 Dec;8(12):1112-1119.

Bewertungen

Review for MC-Val-Cit-PAB-dimethylDNA31

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MC-Val-Cit-PAB-dimethylDNA31

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.